Broad spectrum antivirals against dsDNA viruses

CONTEXT

Contrary to bacterial infection that can be treated with various antibiotics viral infection treatments are limited. Even if several treatments have been developed for specific virus infection, broad spectrum antivirals have not been developed yet Also, viruses are known to adapt to treatment and develop resistance, leading to therapeutic failure. Therefore, there is a constant need for new generation of first or best in class molecules that can be positioned in first line treatment or in combination with pre existing therapies.

DESCRIPTION

A collection of 50 antiviral corrole based molecules has been synthesized and tested on a line of human and animal viruses. Some of these compounds display selectivity index of around 500 and good PK profile No acute toxicity has been detected in vivo. These compounds show good efficacy when used alone and
some also display synergistic action with gold standard and are active on resistant strains. They are also easy to synthesize in a one to two step reaction Upscaling
production up to 25 g is available.

COMPETITIVE ADVANTAGES

• Broad spectrum activity
• Activity on resistant strains
• Antiviral synergistic action with gold standard
• Easy synthesis and available upscaling

MARKETS & APPLICATIONS

Pharmaceutical human & animal antivirals: 

• Treatment of Pox and Herpes viruses infections
• Antiviral for oncolytic viruses
• Biodefense

DEVELOPMENT STAGE

In vitro activity demonstrated on pox and herpes viruses infected cells - In vivo testing is currently in progress

RESEARCH TEAM

UMR CNRS 6302 Institute of Molecular Chemistry of the University of Burgundy (ICMUB)

INTELLECTUAL PROPERTY

Two european patent applications (2017 November) and PCT extensions (2018 November)

TARGET PARTNERSHIP

Patent licensing

CONTACT-US

Ludmila MONTEIRO
Business Developer
+33 (0)6 31 10 21 21
ludmila.monteiro@sayens.fr